Hydrocortison Hoechst (Hydrocortisone)

Hydrocortison Hoechst is indicated for several clinical situations where glucocorticoid therapy is required.

• Replacement therapy in primary or secondary adrenal insufficiency.
• Management of acute inflammatory disorders such as arthritis or dermatitis.
• Treatment of severe allergic reactions, including anaphylaxis adjunct.
• Short‑term control of exacerbations in chronic respiratory diseases like asthma.
• Adjunct therapy in certain autoimmune conditions when systemic anti‑inflammatory effect is needed.

• Hydrocortison Hoechst exerts its effect by binding to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. The activated receptor complex up‑regulates anti‑inflammatory proteins such as annexin‑A1 and suppresses pro‑inflammatory cytokines (e.g., IL‑1, IL‑6, TNF‑α). This genomic action reduces leukocyte migration, capillary permeability, and immune cell activation, resulting in systemic anti‑inflammatory and immunosuppressive outcomes.

Like other systemic glucocorticoids, Hydrocortison Hoechst may be associated with a range of adverse reactions, which vary in frequency and severity.

Common

• Increased appetite or weight gain.
• Mild gastrointestinal discomfort or dyspepsia.
• Fluid retention leading to peripheral edema.
• Mood changes such as irritability or mild anxiety.
• Elevated blood glucose levels, especially in susceptible individuals.

Serious

• Severe hyperglycemia or new‑onset diabetes.
• Hypertension or worsening of pre‑existing high blood pressure.
• Osteoporosis or increased risk of fractures with prolonged use.
• Suppression of the hypothalamic‑pituitary‑adrenal axis.
• Opportunistic infections due to immunosuppression.

When prescribing Hydrocortison Hoechst, clinicians should evaluate several precautionary factors to minimize risk.

• Assess for active infections; glucocorticoids can exacerbate bacterial, viral, or fungal diseases.
• Screen for diabetes mellitus or impaired glucose tolerance before initiating therapy.
• Evaluate bone health, especially in patients with a history of osteoporosis or fractures.
• Use the lowest effective dose for the shortest duration necessary.
• Monitor blood pressure and electrolyte balance during treatment.
• Consider tapering the dose gradually to avoid adrenal insufficiency after prolonged use.
• Avoid use in patients with known hypersensitivity to hydrocortisone.

Hydrocortison Hoechst can interact with other medicines, altering its efficacy or increasing the risk of adverse effects.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce hydrocortisone plasma levels.
• Co‑administration with systemic antifungal agents that are potent CYP3A4 inhibitors (e.g., ketoconazole) which can raise glucocorticoid concentrations.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) due to increased risk of gastrointestinal ulceration.
• Anticoagulants such as warfarin, as glucocorticoids may affect INR stability.
• Vaccines, particularly live attenuated vaccines, because immunosuppression can diminish vaccine efficacy.
• Diuretics, which may exacerbate electrolyte disturbances when combined with glucocorticoids.